Objective To investigate the efficacy of dapagliflozin for overweight/obese patients with type 2 diabetes after 12 weeks of treatment with liraglutide.Methods A total of 93 overweight/obese type 2 diabetes patients who had been treated with liraglutide for just 12 weeks were randomly divided into the liraglutide group (n=46) and the dapagliflozin group (n=47).Patients in the liraglutide group continued to take liraglutide, while the dapagliflozin group switched to dapagliflozin. The treatment lasted 12 weeks in both groups before the changes of blood glucose, weight, waist circumference and blood pressure were compared.Results The blood glucose, weight, waist circumference and blood pressure were significantly lower in both groups after treatment(P<0.01). The extent to which fasting blood glucose [(1.0±0.6)vs(0.8±0.5)] mmol/L, 2-hour postprandial blood glucose[(1.3±0.8)vs(1.4±0.9)] mmol/L, glycated hemoglobin [(1.0±0.5)vs(0.9±0.6)]%, body weight [(1.5±1.4)vs(1.0±1.2)] kg, body mass index[(0.7±0.6)vs(0.5±0.4)] kg/m2, systolic blood pressure[(5.0±3.0)vs(5.0±2.5)]mmHg, and diastolic blood pressure[(3.0±1.0)vs(3.0±1.2)]mmHg (P>0.05) decreased was not statistically different between the two groups. However, the waist circumference of the dapagliflozin group decreased less significantly [(1.9±1.3)vs(0.9±0.8)] cm(P<0.01).Conclusions For overweight/obese patients with type 2 diabetes after liraglutide treatment, switching to dapagliflozin will have the same effect as continued treatment with liraglutide on blood glucose, weight, and blood pressure except for the waist circumference.
Duan C M, Wan T F, Wang Y, et al. Cardiovascular outcomes of liraglutide in patients with type 2 diabetes-a systematic review and meta-analysis[J].Medicine,2019, 98(46):e17860-17866.
[2]
Wharton S, Kuk J L, Luszczynski M, et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery[J]. Clin Obes, 2019, 9(4): e12323-12329.
[3]
Wiviott S D, Raz I, Bonaca M P, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4):347-357.
[4]
Cai X, Ji L, Chen Y, et al. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis[J]. J Diabetes Investig, 2017, 8(4):510-517.
[5]
Sohita D. Dapagliflozin: a review in type 2 diabetes[J]. Drugs, 2019,79(10):1135-1146.
[6]
Mazidi M, Rezaie P, Gao H K, et al. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22528 patients[J]. J Am Heart Assoc,2017,6(6): 1-23.
[7]
Mirabelli M, Chiefari E, Caroleo P,et al. Long-term effectiveness of liraglutide for weight management and glycemic control in type 2 diabetes[J]. Int J Environ Res Public Health, 2019, 17(1): 207-218.
[8]
Zhao X, Huang K, Zheng M, et al. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials[J]. BMC EndocrDisord, 2019, 19(1):4-18.
[9]
Adams J M, Pei H, Sandoval D A, et al. Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons[J]. Diabetes,2018, 67(8):1538-1548.
[10]
Ishii S, Nagai Y, Sada Y, et al. Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series[J]. J Clin Med Res, 2019, 11(3): 219-224.
[11]
Schork A, Saynisch J, Vosseler A,et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy[J]. Cardiovasc Diabetol,2019,18(1):46-58.
[12]
Fadini G P, Bonora B M, Zatti G,et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial[J]. Cardiovasc Diabetol, 2017,16(1): 42-52.
2020, Vol. 31 
